DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rmls76/investigation) has announced the addition of the "Investigation Report on China Rivaroxaban Market, 2010-2019" report to their offering. According to some experts, rivaroxaban and dabigatran are the most promising antithrombotic agents which will add a new milestone to the development of cardiovascular drugs. Rivaroxaban is the first available orally active direct factor Xa inhibitor developed by Ba
| < Prev | Next > |
|---|
